Migraine is one of the most common neurological disorders having a paroxysmal, progressive and often devastating impact on patient’s wellbeing and quality of life. As GDB reports migraine is in the top ten causes of YLDs in general population and is the third cause of disability in both males and females aged 15–49. According to the WHO migraine affects 15–20% of the population and is three times more prevalent in women (18%) than in men (6%) in the United States and Europe. Preventive and/ or acute migraine pharmaceutical treatments show little to good efficacy in relieving attacks in some patients, but many of them might have adverse effects that are contraindicated for individuals with cardiovascular and renal impairments, pregnancy or risk of substance overuse, increasing the probability of an episodic migraine becoming chronic. Thus, making the advancement in treatment an imperative goal for physicians. In this sense, non-invasive neuro-modulatory techniques such as repetitive transcranial magnetic stimulation (rTMS) have shown promising results as new therapeutic approaches for such patients.